NanoLogix Technologies This Site is Under Construction

 The Tecnica Family is based on the:

 NRTK- NanoChannel Rapid Test Kit

BioNanoChannel(TM) Ultra Fast Bacterial Identification Technology:

 

 

Nanologix's patent pending  BioNanoChannel (TM)  Technology (BNC) provides extremely rapid results (identification can be obtained within minutes to hours after sampling), highly sensitive (able to analyze as little as one cell in a sample), very simple and user-friendly (doesn't need sophisticated opto-electronic equipment), applicable to a large number of different liquid, solid, and bioaerosol samples, and is based on utilizing the unique features of the cutting-edge technology, the BioNanoChannel(TM) Plate.

The bottom line for Nanologix's BioNanoChannel Ultra Fast Bacterial Identification Technology is that it is a superior replacement for Petri Dishes. Instead of hours or days to determine what infection a patient has the answer can be obtained in minutes to hours. Not only does this prevent the use of damaging broad spectrum antibiotics which are used because the infection is not identified, it can literally be a matter of life or death identifying the infection quickly so it can be properly treated.  Nanologix is now pursuing commercialization of this technology and looking for large biotech firms to partner with.  The Petri Dish market is over two billion dollars a year.  The same technology can be used in the food industry where fast testing can save money and prevent food poisoning outbreaks.

For national BioDefense needs such as the Anthrax attack that happened in the United States or battlefield situations quick and accurate identification of bacteria is crucial.   Nanologix believes that our BioNanoChannel Technology may be able to make a major contribution to fast, inexpensive, portable and accurate Anthrax identification and have started research into this possibility. The inherent advantages are that it should be able to determine live from dead bacteria and spores, is highly portable, lower cost, and requires less training than current technologies such as PCR

Diagnostic Kits Technologies:  

NanoLogix originally developed the patented intellectual property incorporated as a basis for Nutra Pharma's (OTC BB: NPHC.OB) Designer Diagnostic test kits. These test kits are currently marketed for use in early detection of infectious human diseases such as tuberculosis and nontuberculosis mycobacterium. NanoLogix has assigned the rights to 11 patents and licensed the rights to 18 others to Nutra Pharma for use in diagnostic test kit development. NanoLogix retains a license for the nanotechnology aspects of the assigned patents and the rights to all nanotechnology aspects of the licensed patents. In exchange for this licensing and assignment, Nanologix receives the greater of either a 6% royalty on gross sales or a significant annual guarantee.  Revenue has started from this arrangement.

 

Additional NanoLogix’s Patents and Applications:  

 Cell Apoptosis Patent:    The non-toxic induction of apoptosis ('cell suicide') for the treatment of cancer.  When a cancer cell comes in contact with a hydrophobic material like paraffin, apoptosis is often induced.  This has many potential applications. A newer Nanologix patent application for using the apoptosis patent in combination with blood dialysis for possible treatment of leukemia has been filed.  The company has been contacted by leukemia researchers seeking collaboration to pursue this method.

 

Silver Nanotube Treatment for Infections:

  Nanologix in 2007 filed a patent for using Silver Nanotube dialysis to kill bacteria and fungus infections in blood.  Bacteria never develop resistance to silver.  Silver was the original antibiotic, before penicillin was developed.  Silver’s drawback was delivery as high doses caused skin discoloration.    As antibiotics are losing their effectiveness, this innovative concept holds promise for an entirely new way to control infections.  It’s a profound concept of treating infections outside the body through contact (not internally administered drugs) to prevent side effects.

 

Bioremediation of Organic Hazardous Substances:

   Our patent #5,994,120 is a method for removing organic hazardous substances in the ground water such as oil refinery spills, leaking gas station tanks, etc. via nontoxic introduction of natural bacteria in conjunction with nontoxic organic materials.  Nanologix has received revenue in the past from this patent and will pursue further commercialization.

   

NanoLogix’s R&D Lab

Nanologix has a fully equipped R&D lab.  The company is able to work on all our technology lines in our lab which is associated with the Ohio BioStart initiative.

 

Patents

Nanologix has an Impressive Portfolio of Granted and Pending Patents With over 30 Patents Granted and over 30 Applied for US Patents Granted and retained solely by Nanologix

#6,274,377 Inducing apoptosis in a mammalian cell

#5,994,120 Method of bioremediation of an organic hazardous substance

Medical Test Kit technology Patents Assigned to Nutra Pharma Inc., with Royalty to NanoLogix. Rights to nanotechnology aspects retained by NanoLogix. Patents also include renewable hydrogen production aspects.

US Patent #
#5,989,902
#5,981,210
#5,935,806
#5,882,920
#5,854,014
#5,846,760
#5,776,722
#5,569,592
#5,472,877
#5,316,918
#5,153,119

Medical Test Kit technology Patents Licensed but not Assigned to Nutra Pharma Inc., with Royalty to NanoLogix. Rights to nanotechnology aspects retained by NanoLogix. Patents also include renewable hydrogen production aspects.

#5,962,306
#5,891,662
#5,882,919
#5,854,013
#5,804,406
#5,801,009
#5,750,363
#5,726,030
#5,721,112
#5,707,824
#5,698,414
#5,677,169
#5,668,010
#5,663,056
#5,654,194
#5,641,645
#5,639,675
#5,637,501

Plus over 30 Patents applied for in the areas of Hydrogen BioReactors, the Rapid BioNanoChannel(TM) Bacteria Diagnostic Technology, potential Leukemia treatment and silver nanotube blood dialysis for non drug antibiotic effect.